Related Experiment Video
Updated: Jul 28, 2026
One Minute, Sub-One-Watt Photothermal Tumor Ablation Using Porphysomes, Intrinsic Multifunctional Nanovesicles
Published on: September 17, 2013
Synthesis of porphyrin-formononetin derivatives and their anti-tumor activity studies
Lingyan Yang1, Shan He2, Chen Tang1
1Institute of Pharmacy & Pharmacology, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, University of South China, Hengyang, 421001, Hunan, China.
Abstract:
Photodynamic therapy (PDT) has received much attention in cancer treatment because of its low toxicity and side effects. In this study, we successfully synthesized 14 novel porphyrin-formononetin derivatives. In reactive oxygen species detection experiments, the target compounds 4a-6d caused a significant decrease in the fluorescence intensity of DPBF compared with the porphyrin parent and formononetin feedstock after illumination, and it was found that the target compound had a higher ROS quantum yield, among which the quantum yield of compound 6c was higher. In the in vitro anti-tumor activity assay, the target compounds 4a-6d exhibited a certain degree of growth inhibition against six cancer cells (A549, MDA-MB-231, HCT-116, HGC-27, DU145, and TCCSUP) under light conditions, whereas the cytotoxicity of the target compounds against the normal cells H9c2 was less. The results of the scratch assay showed that 6c could inhibit the growth of tumor cells by inhibiting the migration of DU145 cells. The experimental results indicate that the target compounds achieve the synergistic effect of PDT and chemotherapy.
Insights
Researchers developed novel porphyrin-formononetin compounds for photodynamic therapy (PDT). These compounds show enhanced reactive oxygen species generation and selective cancer cell inhibition, indicating a synergistic PDT and chemotherapy effect.
Area of Science:
- Medicinal Chemistry
- Photodynamic Therapy
- Cancer Research
Background:
- Photodynamic therapy (PDT) is a promising cancer treatment modality due to its low toxicity.
- Novel photosensitizers are crucial for enhancing PDT efficacy.
- Formononetin derivatives offer potential for developing new therapeutic agents.
Purpose of the Study:
- To synthesize and characterize novel porphyrin-formononetin derivatives.
- To evaluate the reactive oxygen species (ROS) generation capabilities of the synthesized compounds.
- To assess the in vitro anti-tumor activity and selectivity of these compounds.
Main Methods:
- Synthesis of 14 novel porphyrin-formononetin derivatives.
- Reactive oxygen species (ROS) detection using DPBF fluorescence quenching.
- In vitro anti-tumor assays against six human cancer cell lines (A549, MDA-MB-231, HCT-116, HGC-27, DU145, TCCSUP) and normal cells (H9c2).
- Scratch assay to evaluate cell migration inhibition.
Main Results:
- Synthesized compounds 4a-6d demonstrated significant ROS generation upon illumination, with compound 6c showing the highest ROS quantum yield.
- Compounds 4a-6d exhibited notable in vitro anti-tumor activity against tested cancer cell lines with reduced toxicity to normal cells.
- Compound 6c effectively inhibited DU145 cell migration, suggesting anti-metastatic potential.
Conclusions:
- The novel porphyrin-formononetin derivatives possess potent photodynamic and cytotoxic activities.
- Compound 6c is a promising candidate for synergistic photodynamic therapy and chemotherapy.
- These findings support the development of these derivatives as effective anti-cancer agents.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase